Correlation of Malassezia Species with Clinical Characteristics of Pityriasis Versicolor
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod -
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine -
Use of Nifuratel to Treat Infections Caused by Atopobium Species
(19) & (11) EP 2 243 482 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.10.2010 Bulletin 2010/43 A61K 31/422 (2006.01) A61P 15/02 (2006.01) A61P 31/04 (2006.01) A61P 13/02 (2006.01) (2006.01) (21) Application number: 09158221.3 A61P 15/00 (22) Date of filing: 20.04.2009 (84) Designated Contracting States: (72) Inventor: Mailland, Federico AT BE BG CH CY CZ DE DK EE ES FI FR GB GR CH-6900 Lugano (CH) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR (74) Representative: Pistolesi, Roberto et al Designated Extension States: Dragotti & Associati Srl AL BA RS Via Marina 6 20121 Milano (IT) (71) Applicant: Polichem SA 1526 Luxembourg (LU) (54) Use of nifuratel to treat infections caused by atopobium species (57) The present invention is directed to the use of genitalia in both sexes, as well as bacterial vaginosis, or nifuratel, or a physiologically acceptable salt thereof, to mixed vaginal infections in women, when one or more treat infections caused by Atopobium species. The in- species of the genus Atopobium are among the causative vention is further directed to the use of nifuratel to treat pathogens of those infections. bacteriuria, urinary tract infections, infections of external EP 2 243 482 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 243 482 A1 Description [0001] The present invention relates to the use of nifuratel, or a physiologically acceptable salt thereof, to treat infections caused by Atopobium species. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07K 7/60 (2006.01) G01N 33/53 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CI2Q 1/18 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (21) International Application Number: KM, ML, MR, NE, SN, TD, TG). PCT/US2017/063696 (22) International Filing Date: Published: 29 November 201 7 (29. 11.201 7) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/427,507 29 November 2016 (29. 11.2016) US 62/484,696 12 April 2017 (12.04.2017) US 62/53 1,767 12 July 2017 (12.07.2017) US 62/541,474 04 August 2017 (04.08.2017) US 62/566,947 02 October 2017 (02.10.2017) US 62/578,877 30 October 2017 (30.10.2017) US (71) Applicant: CIDARA THERAPEUTICS, INC [US/US]; 63 10 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (US). (72) Inventors: BARTIZAL, Kenneth; 7520 Draper Avenue, Unit 5, La Jolla, CA 92037 (US). DARUWALA, Paul; 1141 Luneta Drive, Del Mar, CA 92014 (US). FORREST, Kevin; 13864 Boquita Drive, Del Mar, CA 92014 (US). -
Seborrheic Dermatitis More Than Meets the Eye
SEBORRHEIC DERMATITIS More than meets the eye Martijn Gerard Hendrik Sanders Financial support for the printing of this thesis was kindly provided by: La Roche-Posay UCB Chipsoft LEO Pharma Louis Widmer L’Oréal Lilly Merz Pharma Van der Bend B.V. Olmed ISBN: 978-94-6361-558-7 Cover illustration by Sara van der Linde Cover design, lay-out and printing by Optima Grafische Communicatie Copyright © M.G.H. Sanders, Rotterdam 2021 All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form by any means without permission from the author, or when appropriate, of the publisher of the publication. Seborrheic Dermatitis More than meets the eye Seborroïsch eczeem Niet alles is wat het lijkt Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. F.A. van der Duijn Schouten en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatvinden op donderdag 24 juni 2012 om 10:30 uur Door Martijn Gerard Hendrik Sanders geboren te Almelo PROMOTIECOMMISSIE Promotor: prof. dr. T.E.C. Nijsten Overige leden: prof. dr. E.P. Prens prof. dr. A.G. Uitterlinden prof. dr. J.L.W. Lambert Copromotor: dr. L.M. Pardo Cortes CONTENTS Chapter 1 General introduction 7 Chapter 2 Dermatological screening of a middle-aged and elderly population: 19 the Rotterdam Study Chapter 3 3.1 Prevalence and determinants of seborrheic dermatitis in a middle 29 aged and elderly population: the Rotterdam Study 3.2 Association between -
Current Options in Antifungal Pharmacotherapy
Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by yeasts and molds continue to be associated with high rates of morbidity and mortality in both immunocompromised and immuno- competent patients. Many antifungal drugs have been developed over the past 15 years to aid in the management of these infections. However, treatment is still not optimal, as the epidemiology of the fungal infections continues to change and the available antifungal agents have varying toxicities and drug- interaction potential. Several investigational antifungal drugs, as well as nonantifungal drugs, show promise for the management of these infections. Key Words: antifungal drugs, invasive fungal infection, amphotericin B, polyenes, invasive aspergillosis, liposomal amphotericin B, L-AmB. (Pharmacotherapy 2008;28(5):614–645) OUTLINE Icofungipen Polyenes Conclusion Mechanism of Action Invasive fungal infections continue to be asso- Clinical Efficacy ciated with high rates of morbidity and mortality Safety in both immunocompromised and immuno- Azoles competent hosts. Amphotericin B deoxycholate Mechanism of Action (AmBd) has been the cornerstone for treatment Clinical Efficacy of invasive fungal infections since the early Safety 1950s. However, new agents have emerged to Echinocandins manage these infections over the past 15 years Mechanism of Action (Figure 1). Although Candida species remain the Clinical Efficacy most common pathogens associated with fungal Safety disease, infections caused by Aspergillus and Investigational Antifungal Drugs and Other Cryptococcus sp, Zygomycetes, and the endemic Nonantifungal Agents fungi (Histoplasma, Blastomyces, and Coccidioides Monoclonal Antibody Against Heat Shock Protein 90 sp) also account for many fungal infections. -
PDF Library/Candidiasis.Pdf 7 Sexually Transmitted Diseases Treatment Guidelines, 2010
COMMISSION DE LA TRANSPARENCE Avis 2 octobre 2013 FLUCONAZOLE MAJORELLE 150 mg, gélule B/1 (34009 395 173 0 8) Laboratoire MAJORELLE DCI fluconazole Code ATC (2012) J02AC01 (Antimycosiques à usage systémique) Motif de l’examen Inscription Liste(s) Sécurité Sociale (CSS L.162-17) concernée(s) Collectivités (CSP L.5123-2) Indication(s) « Traitement des Candidoses vaginales et périnéales aiguës et concernée(s) récidivantes » HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique 1/12 Avis 1 modifié le 28 novembre 2014 SMR SMR modéré ASMR ASMR de niveau V Place dans la Le traitement des candidoses vaginales et périnéales aiguës et récidivantes , stratégie peut être local ou systémique. Dans le cas d’un traitement systémique, il thérapeutique s’agit d’un traitement en dose unique. HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique 2/12 Avis 1 modifié le 28 novembre 2014 01 INFORMATIONS ADMINISTRATIVES ET REGLEMENTAIRES AMM 24/07/2009 (procédure nationale) Conditions de prescription et de Liste I délivrance / statut particulier 2012 J Anti-infectieux généraux à usage systémique J02 Antimycosiques à usage systémique Classification ATC J02A Antimycosiques à usage systémique J02AC Dérivés triazolés J02AC01 Fluconazole 02 CONTEXTE Il s’agit d’une demande d’inscription de la spécialité FLUCONAZOLE MAJORELLE 150 mg en gélule, sur la liste des spécialités remboursables aux assurés sociaux et sur la liste des médicaments agrées à l’usage des collectivités. FLUCONAZOLE MAJORELLE 150 mg est un générique de la spécialité princeps FLUCONAZOLE PFIZER 150 mg. Il existe deux autres spécialités génériques, BEAGYNE 150 mg et FLUCONAZOLE SANDOZ 150 mg. -
Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01 -
EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of -
(Oral and Vaginal) Therapy for Recurrent Vulvovaginal Candidiasis: a Systematic Review Protocol
Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2018-027489 on 22 May 2019. Downloaded from Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol Juliana Lírio,1 Paulo Cesar Giraldo,2 Rose Luce Amaral,2 Ayane Cristine Alves Sarmento,3 Ana Paula Ferreira Costa,3 Ana Katherine Gonçalves3 To cite: Lírio J, Giraldo PC, ABSTRACT Strengths and limitations of this study Amaral RL, et al. Antifungal Introduction Vulvovaginal candidiasis (VVC) is frequent (oral and vaginal) therapy in women worldwide and usually responds rapidly to for recurrent vulvovaginal ► Two independent reviewers will select studies, ex- topical or oral antifungal therapy. However, some women candidiasis: a systematic tract data without different variables and assess develop recurrent vulvovaginal candidiasis (RVVC), which review protocol. BMJ Open the risk of bias, to indicate through evidence-based 2019;9:e027489. doi:10.1136/ is arbitrarily defined as four or more episodes every medicine if there is a more effective antifungal ther- bmjopen-2018-027489 year. RVVC is a debilitating, long-term condition that can apeutic regimen for the treatment of recurrent vul- severely affect the quality of life of women. Most VVC is Prepublication history for vovaginal candidiasis. ► diagnosed and treated empirically and women frequently this paper is available online. ► There may be a limitation of outcome from treat- To view these files, please visit self-treat with over-the-counter medications that could ment variation, routes of administration, different the journal online (http:// dx. doi. contribute to an increase in the antifungal resistance. The doses and quality of the randomised trials used in org/ 10. -
(12) United States Patent (10) Patent No.: US 8.404,751 B2 Birnbaum Et Al
USOO8404751B2 (12) United States Patent (10) Patent No.: US 8.404,751 B2 Birnbaum et al. (45) Date of Patent: Mar. 26, 2013 (54) SUBUNGUICIDE, AND METHOD FOR 5,696,105 A * 12/1997 Hackler ........................ 514f172 TREATING ONYCHOMYCOSIS 5,894,020 A 4, 1999 Concha 6,008,173 A * 12/1999 Chopra et al. ................ 51Of 152 6,043,063 A 3/2000 Kurdikar et al. (75) Inventors: Jay E. Birnbaum, Montville, NJ (US); 6,143,794. A 11/2000 Chaudhuri et al. Keith A. Johnson, Durham, NC (US) 6,162,420 A 12/2000 Bohn et al. 6,207,142 B1 3/2001 Oddset al. (73) Assignee: Hallux, Inc., Santa Ana, CA (US) 6,221,903 B1 4/2001 Courchesne 6,224,887 B1 5, 2001 Samour et al. (*)c Notice:- r Subject to any disclaimer, the term of this 6,264,9276,231,840 B1 7/20015, 2001 MonahanBuck patent is extended or adjusted under 35 6.361,785 B1 3/2002 Nair et al. U.S.C. 154(b) by 233 days. 6,733,751 B2 5, 2004 Farmer 6,846,837 B2 1/2005 Maibach et al. (21) Appl. No.: 12/606,324 6,878,365 B2 * 4/2005 Brehove .......................... 424,61 7,074,392 B1 7/2006 Friedman et al. 2002/017343.6 A1 11/2002 Sonnenberg et al. (22) Filed: Oct. 27, 2009 2002/0183387 A1 12/2002 Bogart 2003/OOOT939 A1 1/2003 Murad (65) Prior Publication Data 2003/0207971 A1* 11/2003 Stuartet al. ................... 524, 274 2004.0062733 A1 4/2004 Birnbaum US 201O/OO48724 A1 Feb.